Skip to main content
Equibles
KLRA logo

KLRA · Kailera Therapeutics, Inc.

Track KLRA — free

Use KLRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KLRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.61 +1.61 (+16.10%) At close · Oct 9
Russell 2000 member Rebalance outlook locked
Market Cap
$1.51B
Shares
129.64M
Volume · Oct 9 2.18M Avg daily vol (3M) 881.63K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.61 Open$10.13 Day$9.98–11.81 Available close range$10.00–26.00 Avg vol 30d1.3M Short int8.7M · 6.7% float · 5.6d Short vol52% Last earningsAug 12, 2026 DataApr 2026–Oct 2026 Filing10-Q · Aug 12

The closing range uses available history since Apr 17, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$916.74M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10,222,660,700.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
6.7%
Latest settlement · 5.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −23%
below
RSI (14) 43
neutral
MACD trend Positive
52-week position 10%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −17%
trailing
6-month return −53%
trailing
Relative strength −63%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
4 of 100 funds reported for Sep 30 · net +59.6K sh shares · +4 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.70% of float · ▲ +45.6% MoM · 5.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
100 holders — 13F breadth
Squeeze score 60
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 72%
annualized · 1-yr
Max drawdown −62%
past year
ATR 8.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−23% Bearish
RSI (14)
43 Neutral
MACD trend
Positive Bullish
52-week position
10% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
4 of 100 funds reported for Sep 30 · net +59.6K sh shares · +4 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.70% of float · ▲ +45.6% MoM · 5.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
100 holders — 13F breadth
Price context
position in its available closing range
Range low $10 Now $12 · 10% Range high $26
vs 50-day avg -23%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KLRA
Kailera Therapeutics, Inc.
this stock
$1.51B — — — 6.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $129.29B +12.5% +46.2% 29.7 1.8%
MRNA
Moderna, Inc.
 $89.83B +663.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.86B -3.3% +20.8% 18.5 2.1%
CSLLY
Csl Ltd
 $61.83B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
104
% held
90.2%
Reported
4 of 100
Top holder
Bain Capital Investors LLC
Held Float
View
Held by Funds
Fund positions
125
View
Short & Settlement
Short Interest Rising
Shares short
8.7M
Days to cover
5.6d
Change
+2.7M sh
View
Short Volume
Short vol %
52%
As of
Oct 9, 2026
Short Total
View
Fails to Deliver
FTD shares
7.9K
Value
$129.5K
As of
Sep 2, 2026
View
Off-Exchange
Off-exchange %
43.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
6
View
Earnings & Events
Webcasts
Last webcast
Aug 12, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
KLRA +11.7% -16.7% -52.8% +1.7% —
SPY +1.2% +1.9% +9.9% +2.1% +14.2%
vs SPY +10.6% -18.6% -62.7% -0.4% —
Key facts CIK 2096997 CUSIP 482931102 13F (30d) 5 filings 5 filers Visit website Investor relations